Escherichia coli are recognized, and concerns exist about emerging fluoroquinolone resistance.
sistance rates to TMP-SMX and ciprofloxacin or levofloxacin were ∼21% and ∼5%, respectively [6] . There have been increasing reports of fluoroquinolone-resistant E. coli UTIs, particularly from outside North America, where resistance rates as high as 40% have been observed [7] [8] [9] [10] [11] [12] [13] . However, the degree to which laboratory-and hospital-based surveillance accurately reflects rates of drug resistance in the community and to which international observations presage US susceptibility trends is unclear.
In vitro susceptibility of E. coli to the treatment antibiotic appears to be an important determinant of the clinical outcome of UTI. In a US study involving women with acute uncomplicated pyelonephritis that was conducted during 1994-1997, !1% of E. coli isolates were resistant to ciprofloxacin, and 19% were resistant to TMP-SMX [14] . Ciprofloxacin treatment was associated with greater clinical and bacteriological cure rates than was TMP-SMX treatment, largely because of lower cure rates among TMP-SMX-treated women infected with TMP-SMX-resistant E. coli. Since these findings, fluoroquinolones have been recommended as the treatment of choice for this infection [15] .
For patients with acute uncomplicated cystitis, selective use of TMP-SMX continues to be recommended (i.e., in communities in which the prevalence of E. coli resistance to TMP-SMX is not known to be у20% among patients without risk factors associated with E. coli resistance to TMP-SMX, such as TMP-SMX use within 30 days before presentation or recent hospitalization) [16] [17] [18] [19] [20] [21] [22] . However, the prevalence of E. coli resistance to TMP-SMX among patients with acute uncomplicated pyelonephritis and the extent to which antibiotic resistance risk stratification could guide empirical therapy for upper UTIs is unknown.
Therefore, we conducted a study involving adults presenting to 11 US emergency departments (EDs) with pyelonephritis during 2001-2004 to determine rates of E. coli resistance to TMP-SMX, fluoroquinolones, and other antimicrobials. Data were collected at the time of evaluation to carefully distinguish uncomplicated community-acquired infections from complicated and/or health care-associated infections. Among women with uncomplicated pyelonephritis, the effect of prior antibiotic exposure and other potential risk factors on E. coli resistance to TMP-SMX was evaluated.
PATIENTS AND METHODS
Participants. Adults presenting to the EMERGEncy ID NET, a network of 11 university-affiliated, urban US EDs with a total annual visit census of ∼900,000, were recruited [23] . Institutional review board approval was obtained at all sites. Patients aged у18 years who presented to a network hospital from July 2000 through October 2004 and who (1) had flank pain and/ or costovertebral tenderness, (2) had a temperature у38ЊC measured by any method (i.e., oral, rectal, or axillary), and (3) had received a presumptive diagnosis of pyelonephritis (i.e., the patient received treatment for this infection) were enrolled.
Design. This was a cross-sectional study involving a convenience sample of prospectively identified patients.
Measurements. Demographic characteristics; patients history, including information on urinary tract abnormalities, UTIs, health care setting exposure, significant comorbidities, and immunocompromising conditions; antibiotic use between 48 h and 2 months before presentation; clinical presentation; and treatments provided were collected by ED physicians at the time of care with use of standardized forms. Patients who had urine specimens that grew 1 uropathogen (у10 4 CFUs/ mL) were considered to have confirmed pyelonephritis; these patients made up the study population. Urine specimens that grew 11 organism were considered to be contaminated, and these cases were excluded.
Urine specimens were collected by midstream clean-catch technique (68% of specimens), urethral catheterization (28%), and other techniques (e.g., sample from a collection bag or suprapubic aspirate; 4%) and were transported to the laboratory in sterile containers. Antimicrobial susceptibility of E. coli isolates was determined at each laboratory for the panel of routinely tested agents. MICs were determined by automated susceptibility testing with use of VITEK commercial panels (bioMérieux) at 8 sites, Microscan (Dade Behring) at 2 sites, and the Phoenix Instrument System (Becton Dickinson) at 1 site, according to the manufacturers' instructions. MIC breakpoints and quality-control protocols were based on standards of the Clinical Laboratory Standards Institute [24] . E. coli isolates were tested for antibiotic susceptibility to ampicillin, TMP-SMX, gentamicin, cefazolin, ceftriaxone and/or cefotaxime, and ciprofloxacin and/or levofloxacin. MIC breakpoints for resistance were as follows: ampicillin, у32 mg/mL; TMP-SMX, у4/ 76 mg/mL; cefazolin, у32 mg/mL; cefotaxime, у64 mg/mL; ceftriaxone, у64 mg/mL; levofloxacin, у8 mg/mL; and ciprofloxacin, у4 mg/mL. Isolates that were not resistant to any of these agents were considered to be susceptible.
Patients were classified as having complicated pyelonephritis if they had a current or preexisting functional or anatomical urinary tract abnormality or a current immunocompromising condition (specifically, diabetes, active cancer, systemic corticosteroid use, and HIV infection) or were pregnant or male. The other patients were categorized as having uncomplicated pyelonephritis. Current complicating features were based on clinical findings or laboratory studies in the ED and included pregnancy; diabetes; presence of a bladder catheter, ureteral stent, or percutaneous nephrostomy tube; prostatitis; nephrolithiasis; renal or perirenal abscess; and urinary retention. A history of chronic debilitating illness, such as chronic obstructive pulmonary disease or heart or hepatic failure, was recorded but not considered to be a criterion for complicated infection. Health care-associated infections were those that occurred in patients who were hospitalized during the 30 days before presentation or who resided in a nursing home at the time of presentation; other patients were considered to have community-acquired infections. Urinalysis was performed at local laboratories. Pyuria was defined as 15 leukocytes per mL by highpower field microscopic evaluation of centrifuged urine samples (at 9 sites) and by an automated International Remote Imaging Systems instrument (at 2 sites). Leukocyte esterase dipstick testing was performed for various assays, and leukocyte esterase was reported as present or not present.
Statistical analysis. Data were analyzed with use of SAS, version 9.1 (SAS). Descriptive statistics were used to summarize patient characteristics and prevalence of antimicrobial resistance. ORs and 95% CIs were calculated with use of EpiInfo, version 6 (Centers for Disease Control and Prevention) to determine associations between epidemiologic and clinical characteristics and presence or absence of TMP-SMX-resistant E. coli infection. All reported P values are 2 sided and were not adjusted for multiple testing.
RESULTS
A total of 1272 patients with acute pyelonephritis were enrolled; 977 (77%) of these patients had a urine culture performed. Patients who did and did not have urine cultures performed were similar in terms of anticipated antimicrobial-resistance risk factors; however, those who had urine cultures performed were more likely to have fever (29% vs. 20%) and to be hospitalized (32% vs. 15%) and were less likely to receive oral antimicrobial therapy (74% vs. 88%). Of the 977 patients who had a urine culture performed, 288 (29%) were excluded from analysis; there was no growth on urine culture for 179 patients (18%), an organism thought to be a contaminant grew for 74 (8%), !10 4 CFUs/mL grew for 12 (1%), and 11 organism grew for 24 (2%; the groups were not exclusive). The study population consisted of 689 patients (71%) whose specimen grew a single uropathogen on culture and who thus had confirmed pyelonephritis. Leukocyte esterase was present in 523 (88%) of 592 patients, and microscopic pyuria was present in 550 (92%) of 597 patients.
The median age of the study population was 31 years (range, 18-81 years), and 90% of the patients were female. Of the 689 patients, 649 (94%) had community-acquired infections, and 40 (6%) had health care-associated infections (30 of whom had been hospitalized within 30 days before presentation and 12 of whom resided in a nursing home). Six hundred eightyone (99%) of 689 patients had disposition information available; of these 681 patients, 286 (42%) were discharged home within 6 h, 182 (27%) were discharged after 16 h in the ED, and 213 (31%) were admitted to the hospital (71 had uncomplicated cases, and 142 had complicated cases). Of the 689 patients, 429 women (62%) had uncomplicated pyelonephritis, and 260 patients (38%) had complicated pyelonephritis. Common complicating features were diabetes (in 35% of patients), pregnancy (18%), and male sex (25%), with 67% of men having other complicating factors. The epidemiological, clinical, and laboratory characteristics of the study population are summarized in table 1.
The types and distribution of uropathogens in patients with uncomplicated and complicated pyelonephritis are summarized in For women with uncomplicated pyelonephritis, rates of E. coli antibiotic resistance are summarized in table 3. TMP-SMX resistance was found in 102 (27%) of 384 isolates; the mean site rate was 24% (median, 21%; range, 13%-45%). Frequencies of antibiotic resistance among women with uncomplicated pyelonephritis with and without various potential antibiotic-resistance factors are summarized in table 4. Only exposure to TMP-SMX within 2 days before presentation and Hispanic ethnicity were associated with E. coli resistance to this antibiotic; however, resistance rates among those patients lacking these risk factors were 25% and 19%, respectively. The effect of Hispanic ethnicity appeared to be independent of study location. TMP-SMX exposure 3-60 days before exposure and exposure to other antibiotics up to 60 days before exposure were not associated with antibiotic resistance.
Among women with uncomplicated pyelonephritis due to E. coli, ciprofloxacin-resistant E. coli was found in 4 (1%) of 276 isolates, with a mean site rate of 1% (median, 0%; range, 0%-5%), and levofloxacin-resistant E. coli was found in 7 (2%) of 291 isolates, with a mean site rate of 3% (median, 0%; range, 0%-17%). At the 1 site with a 17% rate of levofloxacin resistance (Kansas City, MO), 1 of 6 isolates was resistant to lev- ofloxacin, and ciprofloxacin susceptibility was not tested. Among isolates tested for both, ciprofloxacin and levofloxacin susceptibilities were concordant. Among 314 women with uncomplicated pyelonephritis due to E. coli who were discharged after ED care, 131 (42%) were treated with levofloxacin, 105 (33%) were treated with ciprofloxacin, 30 (10%) were treated with TMP-SMX, and 15 (4.8%) were treated with cephalexin. Among 226 women treated as outpatients for whom data were available regarding their oral antimicrobial treatment and pathogen susceptibility, 15 (6.6) were treated with an antibiotic that lacked in vitro activity against their E. coli infection: 2 (1.9%) of the 104 women who received ciprofloxacin, 3 (3.1%) of the 96 who received levofloxacin, and 10 (38%) of the 26 who received TMP-SMX. Follow-up information was not available.
Among patients with complicated pyelonephritis due to E. coli, ciprofloxacin-resistant E. coli was found in 8 (7%) of 122 isolates, with a mean site rate of 5% (median, 0%; range, 0%-17%; 17% represents 1 of 6 isolates), and levofloxacin-resistant E. coli was found in 10 (7%) of 150 isolates, with a mean site rate of 6% (median, 0%; range, 0%-29%; 29% represents 2 of 7 isolates).
DISCUSSION
To our knowledge, this is the first syndromic surveillance study of the prevalence and risk factors for uropathogen antimicrobial resistance among prospectively identified patients with acute pyelonephritis. Understanding the prevalence of antimicrobial resistance is important, because clinical failure has been associated with in vitro resistance to antibiotic treatment for UTI. This has been observed for TMP-SMX treatment of acute cystitis and uncomplicated pyelonephritis [14, 25] .
Resistance surveillance surveys of laboratory isolates may exaggerate the prevalence of resistance among uropathogens from patients with community-acquired UTIs. Patients for whom cultures are performed and who present to hospitals may be more likely to have experienced treatment failure or to have received prior therapy for recurrent infections, compared with patients who do not have cultures performed and present to outpatient clinics. Also, laboratory-based surveillance models with retrospective record review are limited by unclear clinical diagnoses and inaccurate antimicrobial resistance risk data.
There are a few studies of infection due to TMP-SMXresistant E. coli that involve prospectively identified women with acute community-acquired uncomplicated cystitis. One European study (1999) (2000) found that the mean rate of E. coli resistance to TMP-SMX in 17 countries was 14% (range, 5%-27%) [5] . In studies from Denver (1998), Baltimore (2002 Baltimore ( -2006 , and California (2005), rates of infection due to TMP-SMX-resistant E. coli were 23%, 15%, and 16%, respectively [26] [27] [28] .
For patients with acute uncomplicated pyelonephritis who were prospectively identified at 11 geographically diverse urban and academically affiliated EDs during 2001-2004, the mean site rate of E. coli resistance to TMP/SMX was 24%, with site rates varying from 13% to 45%. E. coli was the infecting pathogen in 94% of these cases. These results appear to confirm the high rate of TMP-SMX resistance among uropathogenic E. coli in the United States and are consistent with the most recently published North American Urinary Tract Infection Collaborative Alliance survey of outpatient urinary isolates obtained during 2003-2004 [6] . A limitation of our study is that the findings were for a convenience sample of patients from urban, university-affiliated medical center EDs and may not be fully representative.
Concerns have also been expressed about the emergence of fluoroquinolone-resistant E. coli, which has been observed primarily outside North America [7] [8] [9] [10] [11] [12] [13] . The present study found NOTE. TMP-SMX, trimethoprim-sulfamethoxazole. a One ciprofloxacin-resistant isolate at the Charlotte site was not tested for levofloxacin susceptibility. b The levofloxacin-resistant isolates at the Los Angeles and Kansas City sites were not tested for ciprofloxacin susceptibility.
that fluoroquinolone resistance among E. coli isolates causing acute uncomplicated pyelonephritis remained low during 2001-2004, with a mean site rate of !3%. This finding is consistent with the North American Urinary Tract Infection Collaborative Alliance study and a cross-sectional study involving college students with UTIs that found that rates of ciprofloxacin-resistant E. coli infection remained stable, from 1% to 3%, during 1999-2005 [6, 28] . At 1 of our study sites, the levofloxacin resistance rate was 17%, although this rate was derived from 1 resistant isolate. Among patients with complicated pyelonephritis, rates of fluoroquinolone-resistant E. coli infection were higher than those among patients with uncomplicated pyelonephritis, with mean site rates of 5%-6% (median, 0%; 1 site reported a rate of 29%). Previous case-control studies identified risk factors for TMP-SMX resistance in UTI [16] [17] [18] [19] , which has led to the recommendation to stratify women on the basis of their risk of acute uncomplicated cystitis. TMP-SMX has been recommended for patients in communities in which the prevalence of E. coli resistance to TMP-SMX is not known to be у20% among patients without risk factors associated with E. coli resistance to TMP-SMX, such as TMP-SMX use within 30 days before presentation or recent hospitalization [20] . A retrospective study conducted from 1995 through 1997 that involved male and female ED patients with various types of UTI found that diabetes (OR, 3.1; 95% CI, 1.1-5.7), recent hospitalization (OR, 2.5; 95% CI, 1.1-5.7), current antibiotic use (OR, 4.5; 95% CI, 2.0-10.2), and TMP-SMX use within the previous 3 months (OR, 5.1; 95% CI, 2.2-11.5) were independent predictors of the presence of TMP-SMX-resistant coliforms [16] . In the present study, diabetes was a criterion for complicated infection, for which TMP-SMX would not be a recommended as empirical treatment, and exposure to health care settings within 30 days before presentation was not found to be associated with E. coli resistance to TMP-SMX. A prospective study conducted from 1992 through 1999 that involved women with uncomplicated cystitis found that antibiotic use (with an antibiotic other than TMP-SMX) within 2 weeks before presentation (OR, 2.4; 95% CI, 1.1-5.0), TMP-SMX use within 2 weeks before presentation (OR, 16.7; 95% CI, 2.9-97.0), and 3 UTIs within 12 months before presentation (OR, 1.7; 95% CI, 0.6-4.9) were associated with TMP-SMX-resistant E. coli infection [17] . A case-control study conducted from 1993 through 1995 found that TMP resistance to any uropathogen was associated with exposure to TMP or other antibiotics for 3 days to 6 months for patients with any type of UTI [18] .
The present investigation examined women with acute uncomplicated pyelonephritis and revealed that risk stratification appeared to be less helpful for identifying patients infected with TMP-SMX-resistant E. coli. Among those women who had received a diagnosis of an uncomplicated infection, only TMP-SMX treatment within the 2 days before presentation and Hispanic ethnicity were significantly associated with in vitro resistance of E. coli to TMP-SMX, and resistance rates were still ∼20% among women lacking each of these factors. For patients presenting with symptoms and signs of acute infection, it is unlikely that clinicians would choose to continue an antibiotic that demonstrated a lack of clinical effectiveness. Although a larger sample size may have allowed identification of significant risk factor associations not found in this investigation, our study is consistent with more-recent prospective risk factor analyses among women with acute uncomplicated cystitis that did not find evidence that antibiotic exposure was associated with TMP-SMX-resistant E. coli infection [27] [28] [29] . Other iden- tified risk factors in these investigations included Hispanic or Asian ethnicity, prior UTI, and recent travel outside the United States. E. coli clonal group A has been found to be a prominent cause of TMP-SMX-resistant pyelonephritis and cystitis in the United States [28] [29] [30] . Therefore, clonal spread (e.g., physical contact) or exposure (e.g., diet) may be more important factors for the acquisition of TMP-SMX-resistant E. coli strains than is selection pressure of antibiotics.
TMP-SMX treatment of acute uncomplicated cystitis due to a TMP-SMX-resistant E. coli generally results in a longer duration of local symptoms, such as dysuria. However, in acute uncomplicated pyelonephritis, this discordance can result in significant morbidity, including need for hospitalization and progression to severe sepsis (of patients who had blood cultures performed in the present study, ∼20% had bacteremia) [14] . Therefore, these results support the general recommendation that TMP-SMX should not be considered for empirical therapy for patients with acute uncomplicated pyelonephritis, because resistance rates in the United States are generally high, and risk stratification based on recent TMP-SMX use does not appear to be effective. At the time of this study, fluoroquinolone resistance rates were low among women with uncomplicated pyelonephritis but were higher among those with complicated infections. On the basis of these findings, fluoroquinolones (with UTI indications) should remain preferred for empirical treatment for patients with acute uncomplicated pyelonephritis. E. coli isolates that are resistant to either TMP-SMX or fluoroquinolones were susceptible to cephalosporins, including cefazolin, and aminoglycosides, such as gentamicin. However, blactams have been associated with inferior clinical efficacy, compared with fluoroquinolones, for the treatment of UTI [31] [32] [33] , and aminoglycosides are limited by parenteral administration and toxicity concerns [34] . Therefore, further study is needed to determine the optimal therapy for these infections. Routine urine cultures and susceptibility testing are recommended for patients with acute pyelonephritis, because resistance was observed among all oral antimicrobial classes, and rates may have increased since this study was performed.
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